Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Drug-mediated inhibition of Fli-1 for the treatment of leukemia

27 Jan 2012

Abstract excerpt

The Ets transcription factor, Fli-1 is activated in murine erythroleukemia and overexpressed in various human malignancies including Ewing's sarcoma, induced by the oncogenic fusion protein EWS/Fli-1. Recent studies by our group and others have demonstrated that Fli-1 plays a key role in tumorigenesis, and disrupting its oncogenic function may serve as a potential treatment option for malignancies associated with...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acute Myeloid Leukemia Research
Share to Cancer-related Molecular Pathways
Share to Sarcoma Diagnosis and Treatment

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 22829238
DOI: 10.1038/bcj.2011.52

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Drug-mediated inhibition of Fli-1 for the treatment of leukemiaPMID 22829238Read ↗

Identification of diterpenoid compounds that interfere with Fli-1 DNA binding to suppress leukemogenesisSemantic proximity Read ↗

Novel flavagline‐like compounds with potent Fli‐1 inhibitory activity suppress diverse types of leukemiaSemantic proximity Read ↗

Identification of an Inhibitor of the EWS-FLI1 Oncogenic Transcription Factor by High-Throughput ScreeningSemantic proximity Read ↗

FLI-1 is a suppressor of erythroid differentiation in human hematopoietic cellsSemantic proximity Read ↗

Lurbinectedin Inactivates the Ewing Sarcoma Oncoprotein EWS-FLI1 by Redistributing It within the NucleusSemantic proximity Read ↗

Synthesis and Structure–Activity Relationship Studies of Small Molecule Disruptors of EWS-FLI1 Interactions in Ewing’s SarcomaSemantic proximity Read ↗

Signature-Based Small Molecule Screening Identifies Cytosine Arabinoside as an EWS/FLI Modulator in Ewing SarcomaSemantic proximity Read ↗

Ewing's Sarcoma Oncoprotein EWS–FLI1: The Perfect Target Without a Therapeutic AgentSemantic proximity Read ↗

Dual targeting of EWS-FLI1 activity and the associated DNA damage response with trabectedin and SN38 synergistically inhibits Ewing sarcoma cell growth.Semantic proximity Read ↗

Targeted Therapy of Ewing's SarcomaSemantic proximity Read ↗

Therapeutic opportunities in Ewing sarcoma: EWS-FLI inhibition via LSD1 targetingSemantic proximity Read ↗

Gene expression signature based screening identifies ribonucleotide reductase as a candidate therapeutic target in Ewing sarcomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.